Cargando…

Lower-dose prescriptions in the post-marketing situation and the influencing factors thereon

The dosage of pharmaceuticals is determined through the process of clinical development and approval review based on clinical trial results; however, the information obtained from clinical trials before approval is limited. Some pharmaceutical products are used at doses lower than those approved for...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogata, Akiko, Kaneko, Masayuki, Narukawa, Mamoru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6570026/
https://www.ncbi.nlm.nih.gov/pubmed/31199847
http://dx.doi.org/10.1371/journal.pone.0218534
_version_ 1783427247596634112
author Ogata, Akiko
Kaneko, Masayuki
Narukawa, Mamoru
author_facet Ogata, Akiko
Kaneko, Masayuki
Narukawa, Mamoru
author_sort Ogata, Akiko
collection PubMed
description The dosage of pharmaceuticals is determined through the process of clinical development and approval review based on clinical trial results; however, the information obtained from clinical trials before approval is limited. Some pharmaceutical products are used at doses lower than those approved for post-marketing use. The aim of this study was to reveal the actual state of lower-dose prescriptions for post-marketing clinical use of pharmaceuticals. We investigated the factors related to the deviation based on therapeutic area, detailed statement of the approved dosage, clinical data package, and post-marketing requirement. Among the new molecular entities approved in Japan between January 2005 and December 2014, we identified products that are orally administered and have the same daily dose for different indications, if any. For these products, we collected information on the actual daily dose from the medical information databases of Medical Data Vision Co., LTD. and JammNet Co., LTD. Products whose dose was lower than the approved dose (maintenance dose excluding the initial dose) in ≥ 30% prescriptions in 2015 were defined here as “lower-dose prescription drugs.” We identified 27 lower-dose prescription drugs out of 113 products investigated. The results of the multivariate analysis revealed that factors related to the Anatomical Therapeutic Chemical classification and the detailed statement of the approved dosage significantly influenced the occurrence of lower-dose prescription, whereas the factors related to clinical data package and post-marketing requirements did not. These results suggest the limitation in determining an optimal dosage for the actual clinical use of a drug based on the information obtained from clinical trials conducted before approval, emphasizing the importance of reexamining the optimal dosage that is applicable to a greater number of patients after marketing, if necessary. We believe that the utilization of real-world data could be of help in this regard.
format Online
Article
Text
id pubmed-6570026
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-65700262019-06-20 Lower-dose prescriptions in the post-marketing situation and the influencing factors thereon Ogata, Akiko Kaneko, Masayuki Narukawa, Mamoru PLoS One Research Article The dosage of pharmaceuticals is determined through the process of clinical development and approval review based on clinical trial results; however, the information obtained from clinical trials before approval is limited. Some pharmaceutical products are used at doses lower than those approved for post-marketing use. The aim of this study was to reveal the actual state of lower-dose prescriptions for post-marketing clinical use of pharmaceuticals. We investigated the factors related to the deviation based on therapeutic area, detailed statement of the approved dosage, clinical data package, and post-marketing requirement. Among the new molecular entities approved in Japan between January 2005 and December 2014, we identified products that are orally administered and have the same daily dose for different indications, if any. For these products, we collected information on the actual daily dose from the medical information databases of Medical Data Vision Co., LTD. and JammNet Co., LTD. Products whose dose was lower than the approved dose (maintenance dose excluding the initial dose) in ≥ 30% prescriptions in 2015 were defined here as “lower-dose prescription drugs.” We identified 27 lower-dose prescription drugs out of 113 products investigated. The results of the multivariate analysis revealed that factors related to the Anatomical Therapeutic Chemical classification and the detailed statement of the approved dosage significantly influenced the occurrence of lower-dose prescription, whereas the factors related to clinical data package and post-marketing requirements did not. These results suggest the limitation in determining an optimal dosage for the actual clinical use of a drug based on the information obtained from clinical trials conducted before approval, emphasizing the importance of reexamining the optimal dosage that is applicable to a greater number of patients after marketing, if necessary. We believe that the utilization of real-world data could be of help in this regard. Public Library of Science 2019-06-14 /pmc/articles/PMC6570026/ /pubmed/31199847 http://dx.doi.org/10.1371/journal.pone.0218534 Text en © 2019 Ogata et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Ogata, Akiko
Kaneko, Masayuki
Narukawa, Mamoru
Lower-dose prescriptions in the post-marketing situation and the influencing factors thereon
title Lower-dose prescriptions in the post-marketing situation and the influencing factors thereon
title_full Lower-dose prescriptions in the post-marketing situation and the influencing factors thereon
title_fullStr Lower-dose prescriptions in the post-marketing situation and the influencing factors thereon
title_full_unstemmed Lower-dose prescriptions in the post-marketing situation and the influencing factors thereon
title_short Lower-dose prescriptions in the post-marketing situation and the influencing factors thereon
title_sort lower-dose prescriptions in the post-marketing situation and the influencing factors thereon
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6570026/
https://www.ncbi.nlm.nih.gov/pubmed/31199847
http://dx.doi.org/10.1371/journal.pone.0218534
work_keys_str_mv AT ogataakiko lowerdoseprescriptionsinthepostmarketingsituationandtheinfluencingfactorsthereon
AT kanekomasayuki lowerdoseprescriptionsinthepostmarketingsituationandtheinfluencingfactorsthereon
AT narukawamamoru lowerdoseprescriptionsinthepostmarketingsituationandtheinfluencingfactorsthereon